AARD Aardvark Therapeutics, Inc. Common Stock
Healthcare$4.20-7.49%ClosedMarket Cap: $91.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.14
P/S
0.00
EV/EBITDA
-0.49
DCF Value
$2.06
FCF Yield
-62.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.7%
ROA
-70.9%
ROIC
-85.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-22.5M | $-21.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-18.7M | $-17.6M | $— | — |
| FY null | $0.00 | NaN% | $-62.7M | $-57.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-17.7M | $-16.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-15.8M | $-14.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-10.5M | $-9.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-9.4M | $-8.8M | $— | — |
| FY null | $0.00 | NaN% | $-22.8M | $-20.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.1M | $-4.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.1M | $-5.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.2M | $-2.2M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.2M | $-2.0M | $-0.21 | — |